TD Cowen Maintains Buy on Calumet, Lowers Price Target to $18
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Jason Gabelman maintains a Buy rating on Calumet (NASDAQ:CLMT) but lowers the price target from $20 to $18.
August 12, 2024 | 3:13 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
TD Cowen analyst Jason Gabelman maintains a Buy rating on Calumet but lowers the price target from $20 to $18.
The maintained Buy rating suggests continued confidence in Calumet's performance, but the lowered price target indicates some caution regarding its short-term potential. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100